Home > Press > Scottish Medicines Consortium Accepts ABRAXANE® for Use within National Health Service for Scotland
Abstract:
Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
"ABRAXANE's acceptance by the SMC is a significant milestone in our goal to provide patients in the United Kingdom and across Europe with an innovative treatment option," said Jean-François Gimonet, M.D., Vice President, European Operations of Abraxis BioScience.
For further information on the SMC's decision, please visit www.scottishmedicines.org.uk
####
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s product pipeline is based on a proprietary tumor targeting technology known as the nab® (nanoparticle albumin bound) platform. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
For more information, please click here
Contacts:
Investors and Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
+1 310-883-1300
Media Inquiries
Zeno Group
Victoria Fort
+1 202-361-0445
Copyright © Abraxis BioScience
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Nanobiotechnology
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||